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Results A clear cross-sectional and prospective asso-
ciation between serum 25(OH)D and depressive symptom 
score was observed. Fully adjusted models indicated a 
22 % (RR 0.78, 95 % CI 0.68–0.89), 21 % (RR 0.79, 95 % 
CI 0.68–0.90), and 18 % (RR 0.82, 95 % CI 0.71–0.95) 
lower score of depressive symptoms in people in the sec-
ond, third, and fourth 25(OH)D quartiles, when compared 
to people in the first quartile (P for trend <0.0001). After 
2 years of daily 15 µg vitamin D supplementation, similar 
associations were observed. 25(OH)D concentrations did 
not significantly interact with the selected genes.
Conclusion Low serum 25(OH)D was associated with 
higher depressive symptom scores. No interactions between 
25(OH)D concentrations and vitamin D genetic make-up 
were observed. In view of the probability of reverse cau-
sation, we propose that the association should be further 
examined in prospective studies as well as in randomized 
controlled trials.
Keywords Vitamin D · Vitamin D receptor 
polymorphisms · Depression · Elderly · Diabetes
Introduction
Globally almost 350 million people are affected by depres-
sion [1]. Depression is regularly accompanied by a reduced 
quality of life, a variety of comorbidities, and a higher mor-
tality rate [2]. The high prevalence of depression [1], its 
possible consequences [2], plus the unwanted side effects 
[3] that often accompany the use of anti-depressive medica-
tion, indicate the need for preventive measures.
One of the factors that have been suggested to benefi-
cially influence mood and depression is sunlight [4]. Sun-
light, specifically ultraviolet-B radiation, may positively 
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We examined the association of vitamin D status and vita-
min D-related genetic make-up with depressive symptoms 
amongst 2839 Dutch older adults aged ≥65 years.
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Depressive symptoms were measured with the 15-point 
Geriatric Depression Scale. Results were expressed as 
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reduce depressive symptoms by activating the vitamin D 
synthesis in the skin. Mechanistic studies on brain func-
tion support this hypothetical pathway (reviewed in [5, 6]). 
Furthermore, as low vitamin D concentrations have been 
associated with diabetes [7], and diabetes with depression 
[8], vitamin D may also indirectly affect the prevalence of 
depressive symptoms by influencing glucose tolerance. In 
addition, it has been postulated that vitamin D deficiency 
makes the brain more susceptible for neurobiological trig-
gers, like diabetes. Thus, both interaction and modification 
effects by diabetes may be observed when examining the 
association between vitamin D and depression.
One of the groups at risk for a vitamin D deficiency is 
the elderly population, which may be explained by their 
reduced skin capacity to synthesize vitamin D, reduced 
outdoor activities, and decreased dietary intake. Of seven 
observational studies investigating the potential asso-
ciation between 25(OH)D and depression in populations 
aged ≥60 years [9–15], five studies observed significant 
associations [11–15], indicating that persons with higher 
25(OH)D concentrations had a lower probability of being 
depressed when compared to those with lower 25(OH)
D concentrations. Even though most of these studies are 
in favour of vitamin D, it needs to be emphasized that 
there is considerable heterogeneity between studies due 
to differences in study design, populations, sample sizes, 
covariates adjusted for, and method to quantify depres-
sion. Moreover, specific pathways explaining the associa-
tion between 25(OH)D and depression in these popula-
tions have not been investigated. Thus, more—and more 
detailed—evidence is warranted.
More detailed evidence may arise from studies that take 
into account genetic variation in vitamin D-related genes. 
A large genome-wide association study namely observed 
significant differences in 25(OH)D status according to var-
iation in genes that have been linked with vitamin D syn-
thesis (i.e. DHCR7 and CYP2R1) and vitamin D metab-
olism (i.e. CYP24A1 and GC) [16]. Next to these genes 
that may influence 25(OH)D status, associations between 
25(OH)D and depression may also be modified by the effi-
ciency of the vitamin D receptor (VDR), which has been 
identified in brain tissue [17]. Potentially interesting poly-
morphisms of the VDR gene include TaqI/BsmI, ApaI, and 
Cdx2 [18].
In the current study, we investigated the cross-sectional 
association between serum 25(OH)D and the score of 
depressive symptoms in a large sample of older adults. To 
further elucidate the effect of temporality, we also explored 
the association between baseline 25(OH)D concentrations 
and the score of depressive symptoms after 2 years of daily 
15 µg vitamin D3 supplementation. In addition, interactions 
between 25(OH)D and vitamin D-related genes were exam-
ined, specifically DHCR7, CYP2R1, CYP24A1, GC, TaqI/
BsmI, ApaI, and Cdx2. Finally, to further investigate the 
potential underlying mechanisms, also the potential modifi-
cation and mediation effects of self-reported diabetes were 
studied.
Methods
Participants
This study was performed using data of the B-PROOF 
study; a randomized, double-blind, placebo-controlled 
trial designed to assess the efficacy of 2-year daily oral 
supplementation of vitamin B12 and folic acid on fractures 
in mildly hyperhomocysteinemic (plasma homocysteine 
12–50 µmol/l) community-dwelling older adults aged 
≥65 years. Given the known beneficial effect of vitamin 
D on bone health, 15 µg vitamin D3 was added to both 
placebo and treatment tablets. Participants were mainly 
recruited via registries of municipalities in the area of 
the research centres; all inhabitants aged ≥65 years were 
invited by regular mail. In addition, participants were 
recruited by means of information brochures, and meet-
ings that were organized for elderly home residents in the 
area of Rotterdam, Amsterdam, and Wageningen. Finally, 
also potential eligible adults who participated in previous 
studies of the research centres were contacted. For the 
current analyses, only data on baseline 25(OH)D status 
were available; therefore, the impact of the supplementa-
tion regimen on 25(OH)D status over 2 years could not 
be verified by checking the impact on 25(OH)D concen-
trations. However, based on the analyses on the primary 
outcome of the B-PROOF study, we do know that 2661 
participants in this study complied with taking ≥80 % of 
the study tables, including 91.4 % of participants in the 
intervention group and 90.9 % in the placebo group [19]. 
At baseline, 25(OH)D status and depression data were 
available of 2839 participants. After 2 years of follow-up, 
depression data were available for 2544 participants. Fig-
ure 1 shows a detailed overview of the participant flow. 
Details on the study design of this trial have been reported 
previously [20]. The Medical Ethics Committee of Wage-
ningen UR approved the study protocol, and the Medical 
Ethics Committees of VUmc and Erasmus MC confirmed 
local feasibility. All participants gave written informed 
consent.
Biochemical analyses and genotyping
Blood samples were drawn in the morning when par-
ticipants were fasted or had consumed a restricted break-
fast. Samples were stored at −80 °C until determination. 
Serum 25(OH)D was measured by isotope dilution–online 
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solid-phase extraction–liquid chromatography–tandem 
mass spectrometry (ID-XLC-MS/MS) [21]. DNA was iso-
lated from buffy coats. Samples were genotyped for about 
700,000 SNPs using the Illumina Omni Express array, 
covering >90 % of all common variation in the genome. 
Genes selected for this study included genes affect-
ing vitamin D synthesis [i.e. DHCR7 (rs12785878) and 
CYP2R1 (rs10741657)], vitamin D metabolism [CYP24A1 
(rs6013897) and GC (rs2282679)], and vitamin D recep-
tor (VDR) action (VDR rs731236 [TaqI], VDR rs1544410 
[BsmI], VDR rs7975232 [ApaI], and VDR rs11568820 
[Cdx2]).
Mental health
The 15-item Geriatric Depression Scale (GDS) is a widely 
used self-report questionnaire, which is designed to meas-
ure the number of depressive symptoms in an elderly popu-
lation [22]. Scores can range from 0 up to 15 points, where 
higher scores are indicative of more depressive symptoms. 
Scores ranging from 5 to 7 are suggestive of mild depres-
sion, scores ranging from 8 to 9 are indicative of moderate 
depression, and scores ≥10 suggest severe depression [22].
Covariates
Height was measured at baseline with a stadiometer to the 
nearest 0.1 cm. Weight was measured to the nearest 0.5 kg 
with a calibrated analogue scale. Body mass index (BMI) 
was calculated as weight/height2. Data on education level 
(primary, secondary, higher), smoking status (no, current, 
former), physical activity (kcal/day) [23], alcohol con-
sumption (light, moderate, excessive) [24], and disease 
history (i.e. diabetes, hypertension, cardiac disease, stroke/
TIA) were collected by means of questionnaires. Season 
was based on the month of blood sampling. Season of 
blood collection was dichotomized in summer/fall (June–
November) and winter/spring (December–May).
Statistical analyses
Participants characteristics are reported as mean with 
standard deviation (SD), or as percentages. Medians with 
interquartile range were used to report skewed variables. 
Restricted cubic spline regression was used to visualize the 
dose–response between serum 25(OH)D and the depressive 
symptom score, where the model was adjusted for age, sex, 
25(OH)D baseline (n=1267)
GDS baseline (n=1280)
GDS follow-up (n=1149)
B-PROOF population (n=2919)
WUR (n=856)VU medical centre (n=778) Erasmuc MC (n=1285)
25(OH)D baseline (n=846)
GDS baseline (n=845)
GDS follow-up (n=772)
25(OH)D baseline (n=744)
GDS baseline (n=774)
GDS follow-up (n=680)
25(OH)D baseline & GDS baseline (n=2839)
Received 400 µg folic acid, 500 µg
vitamin B12, and 15 µg vitamin D3
(1270)
Received placebo tablet with 15 
µg vitamin D3
(n=1274)
25(OH)D baseline & GDS follow-up (n=2544)
Fig. 1  Flowchart of B-PROOF study data used for the cross-sectional and prospective analyses on 25(OH)D concentrations and depression 
scores. GDS indicates geriatric depression score-15 questionnaire
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BMI, education, smoking, physical activity, alcohol intake, 
season of blood sampling, centre, and self-reported diabe-
tes. The association between serum 25(OH)D and depres-
sion symptom score was further explored using multiple 
Poisson’s regression, providing relative risks (RRs). These 
RRs correspond to the probability of reporting a higher 
score of depressive symptoms when allocated to the sec-
ond, third, or fourth quartile of this population compared 
with participants allocated to the first quartile (i.e. those 
with the lowest 25(OH)D concentrations). Analyses were 
adjusted for age, sex (model 1), BMI, education, smoking, 
alcohol intake, physical activity, season of blood sampling, 
centre (model 2), and diabetes (model 3). Follow-up analy-
ses with model 2 and model 3 were additionally adjusted 
for treatment.
Poisson’s regression was also used to test whether self-
reported diabetes and vitamin D-related genes were associ-
ated with the score of depressive symptoms. Associations 
between self-reported diabetes and the score of depressive 
symptoms were adjusted for age, sex, BMI, education, 
smoking, physical activity, alcohol intake, and centre.
Cox proportional hazards regression was applied to 
examine associations between serum 25(OH)D and self-
reported diabetes. By assigning a constant risk period to all 
participants in the study, the obtained hazard ratio can be 
considered as a prevalence ratio (PR) [25]. This PR corre-
sponds to the probability of having diabetes when allocated 
to the second, third, or fourth quartile of serum 25(OH)D, 
compared with participants allocated to the first quartile of 
serum 25(OH)D (i.e. lowest serum 25(OH)D concentra-
tions). These analyses were adjusted for age, sex (model 1), 
BMI, education, smoking, physical activity, alcohol intake, 
season of blood sampling, and centre (model 2).
Finally, Poisson’s regression was conducted to examine 
potential interactions between 25(OH)D and self-reported 
diabetes, and serum 25(OH)D and vitamin D-related genes. 
All analyses were performed using the statistical package 
SAS, version 9.1 (SAS Institute Inc., Cary, NC, USA), 
except for the restricted cubic spline regression, which was 
analysed in the program R.
Results
Population characteristics are presented in Table 1. Partici-
pants were on average 74.1 ± 6.5 years old and had a mean 
serum 25(OH)D concentration of 56 ± 25 nmol/L; 45 % 
had a concentration below 50 nmol/L, 7 % (baseline)/8 % 
(follow-up) of the participants had ≥5 depressed symp-
toms, and 10 % reported to have diabetes. Over quartiles 
of serum 25(OH)D, significant differences were observed 
for age, sex, BMI, smoking habits, alcohol consumption, 
physical activity level, season of blood sampling, score of 
depressive symptoms, self-reported diabetes, DHCR7, and 
CYP2R1.
Serum 25(OH)D, vitamin D‑related genetic make‑up, 
and score of depressive symptoms
Restricted cubic spline regression showed a modest 
dose–response association between serum 25(OH)D and 
the score of depressive symptoms, levelling off around 
60–65 nmol/L (Fig. 2). Accordingly, testing for nonlin-
earity indicated that this association did not follow a linear 
tendency (P for nonlinearity: 0.04). Fully adjusted Pois-
son’s regression (model 2) subsequently showed a 22 % 
(RR 0.78, 95 % CI 0.68–0.89), 21 % (RR 0.79, 95 % CI 
0.68–0.90), and 18 % (RR 0.82, 95 % CI 0.71–0.95) lower 
score of depressive symptoms in people in the second, 
third, and fourth quartiles of serum 25(OH)D, respectively, 
when compared to people in the first quartile (Table 2). 
Additionally including self-reported diabetes and stroke/
TIA did not substantially change the results: RR 1.0 (ref) 
for the first quartile, RR 0.72 (95 % CI 0.62–0.84) for the 
second quartile, RR 0.74 (95 % CI 0.63–0.87) for the third 
quartile, and RR 0.84 (95 % CI 0.71–0.99) for the upper 
quartile, P for trend 0.0002. Prospective analyses using 
baseline serum 25(OH)D and depression data obtained 
after 2 years of vitamin D supplementation of 15 µg per 
day showed 26, 18, and 21 % less depressive symptoms in 
people in the second, third, and fourth quartiles of serum 
25(OH)D, respectively, when compared to people in the 
first quartile (model 2; Table 2). Adjustment for treatment 
group did not substantially alter the results. Associations 
between vitamin D-related genetic make-up and the score 
of depressive symptoms were non-significant (supplemen-
tary Table I). Moreover, no significant interactions between 
serum 25(OH)D and any of the vitamin D-related genes 
were observed in association with the score of depressive 
symptoms.
Depressive symptoms: is there an interplay 
between serum 25(OH)D and diabetes?
As vitamin D deficiency has been suggested to be a 
potential modifiable risk factor for diabetes [7], and 
diabetics have been shown to be at an increased risk of 
depression [8], also the potential mediation and modifica-
tion effects of diabetes were examined. First of all, the 
association between serum 25(OH)D and self-reported 
diabetes was explored, showing strong associations over 
quartiles of serum 25(OH)D. Crude models showed an 
up to 42 % lower probability of having diabetes in the 
upper quartile, PR 0.58 (95 % CI 0.41–0.82). In the fully 
adjusted model, the associations attenuated, which was 
mainly attributable to the inclusion of BMI [PR 0.77 
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Table 1  Characteristics of Dutch older adults participating in the B-PROOF study per quartile of serum 25(OH)D (nmol/L)
Q1 Q2 Q3 Q4 P value
<36.7 36.7–53.4 53.4–71.7 71.7>
Na 711 718 712 716
25(OH)D (nmol/L) 26 ± 7 45 ± 5 62 ± 5 89 ± 15 <0.0001
Sex, number of men (%) 306 (43) 365 (51) 383 (54) 374 (52) 0.0002
Age, years 76.1 ± 7.4 73.7 ± 6.3 73.7 ± 6.1 72.7 ± 5.7 <0.0001
Body mass index (kg/m2) 27.7 ± 4.6 27.3 ± 3.9 27.3 ± 3.7 26.3 ± 3.5 <0.0001
Smoking status [n (%)] 0.02
 Non-smoker 266 (37) 240 (33) 232 (33) 231 (32)
 Smoker 83 (12) 72 (10) 66 (9) 56 (8)
 Former smoker 362 (51) 406 (57) 414 (58) 429 (60)
Physical activity (kcal/day) 544 ± 385 681 ± 504 679 ± 539 693 ± 451 <0.0001
Educational level [n (%)] 0.07
 Primary education 393 (55) 309 (54) 386 (54) 347 (48)
 Secondary education 142 (20) 151 (21) 155 (22) 152 (21)
 Higher education 176 (25) 177 (25) 171 (24) 217 (31)
Alcohol intake 0.001
 Light 512 (72) 509 (71) 446 (63) 456 (64)
 Moderate 168 (24) 188 (26) 239 (34) 228 (32)
 Excessive 29 (4) 21 (3) 27 (3) 32 (4)
GDS baseline 1 (3) 1 (2) 1 (2) 1 (2) <0.0001
(% GDS score ≥ 5) (11) (5) (6) (6)
GDS follow-up 1 (3) 1 (2) 1 (2) 1 (2) <0.0001
(% GDS score ≥5) (11) (5) (9) (7)
Diabetes [n (%)] 79 (14) 55 (10) 54 (10) 43 (8) 0.01
Hypertension [n (%)] 233 (41) 232 (41) 203 (37) 195 (37) 0.25
TIA/stroke [n (%)] 74 (13) 33 (6) 42 (8) 44 (8) 0.0002
Cardiac disease [n (%)] 166 (29) 138 (25) 130 (24) 123 (23) 0.08
Blood sampling in summer [n (%)] 224 (32) 324 (45) 429 (60) 524 (73) <0.0001
Assigned to B12 and folic acid supplementation [n (%)] 372 (52) 359 (50) 329 (46) 373 (52) 0.07
TaqI/BsmI (n = 2555) 0.75
 0 affected alleles [n (%)] 108 (18) 113 (18) 110 (17) 127 (20)
 1 affected alleles [n (%)] 285 (48) 315 (49) 316 (49) 318 (49)
 2 affected alleles [n (%)] 206 (34) 211 (33) 173 (34) 198 (31)
ApaI (n = 2555) 0.55
 0 affected alleles [n (%)] 137 (23) 141 (22) 155 (24) 134 (21)
 1 affected alleles [n (%)] 299 (50) 328 (51) 302 (46) 316 (49)
 2 affected alleles [n (%)] 163 (27) 170 (27) 192 (30) 193 (30)
Cdx2 (n = 2555) 0.99
 0 affected alleles [n (%)] 21 (4) 23 (4) 25 (4) 25 (4)
 1 affected alleles [n (%)] 180 (30) 201 (31) 193 (30) 200 (31)
 2 affected alleles [n (%)] 398 (66) 415 (65) 431 (66) 418 (65)
DHCR7 (n = 2555) 0.004
 0 affected alleles [n (%)] 50 (8) 59 (9) 49 (7) 37 (6)
 1 affected alleles [n (%)] 261 (44) 252 (40) 232 (36) 233 (36)
 2 affected alleles [n (%)] 288 (48) 328 (51) 368 (57) 373 (58)
CYP2R1 (n = 2555) 0.01
 0 affected alleles [n (%)] 112 (19) 97 (15) 98 (15) 116 (18)
 1 affected alleles [n (%)] 251 (42) 307 (48) 337 (52) 318 (49)
 2 affected alleles [n (%)] 236 (39) 235 (37) 214 (33) 209 (33)
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(95 % CI 0.52–1.14) in the upper quartile] (Table 3). The 
fully adjusted model that did not include BMI, which 
was investigated because BMI might be an intermediate 
in the association between 25(OH)D and diabetes, indi-
cated a 43 % lower probability of having diabetes in the 
upper 25(OH)D quartile. Second, we studied the possi-
ble association between self-reported diabetes and the 
score of depressive symptoms, showing that participants 
with diabetes (n = 231) reported 17 % higher score of 
depressive symptoms than participants without diabe-
tes (n = 2024) after full adjustment, RR 1.17 (95 % CI 
1.00–1.38; Table 4). Mediation was further examined by 
extending the model of serum 25(OH)D and the score 
of depressive symptoms with self-reported diabetes, 
showing that the observed associations even slightly 
strengthened. Including the interaction term serum 
25(OH)D*diabetes did not point towards a modification 
effect in association with the score of depressive symp-
toms (P for interaction = 0.82). Furthermore, removing 
BMI from the fully adjusted model did also not affect 
the association between 25(OH)D concentration and the 
score of depressive symptoms, specifically the RR with 
95 % CI for model 2 without BMI was: Q1 = 1.0 (ref), 
Q2 = 0.77 (0.68–0.89) P = 0.0002, Q3 = 0.78 (0.68–
0.90) P = 0.0004, and Q4 = 0.80 (0.69–0.93) P = 0.003. 
Including the interaction term of serum 25(OH)D*BMI 
did also not point towards a modification effect in asso-
ciation with the score of depressive symptoms (P for 
interaction = 0.11), nor did stratification of the cross-
sectional associations by BMI indicate effect modifica-
tion (Supplementary Table II).
Discussion
This study showed a clear cross-sectional association 
between serum 25(OH)D and the score of depressive 
symptoms as reported by the Geriatric Depression Scale-
15. This association remained after 2 years of vitamin D 
supplementation. No significant associations between vita-
min D-related genetic make-up and the score of depressive 
symptoms were observed, nor did we observe significant 
interactions between vitamin D-related genes and 25(OH)D 
concentrations. There was also no evidence for a potential 
mediation or modification effect by the presence of self-
reported diabetes.
Table 1  continued
Q1 Q2 Q3 Q4 P value
<36.7 36.7–53.4 53.4–71.7 71.7>
CYP24A1 (n = 2555) 0.06
 0 affected alleles [n (%)] 35 (6) 25 (4) 25 (4) 25 (4)
 1 affected alleles [n (%)] 218 (36) 198 (31) 226 (35) 199 (31)
 2 affected alleles [n (%)] 346 (58) 416 (65) 398 (61) 419 (65)
GC (n = 2555) <0.0001
 0 affected alleles [n (%)] 75 (13) 62 (10) 55 (8) 20 (3)
 1 affected alleles [n (%)] 234 (39) 278 (43) 252 (39) 215 (33)
 2 affected alleles [n (%)] 290 (48) 299 (47) 342 (53) 408 (64)
Values are expressed as a mean ± SD, median (IQR) or n (%). Chi-squared tests for categorical variables and one-way analysis of variance for 
continuous variables were performed to compare participant characteristics over quartiles of 25(OH)D
a Dropout after 2 years of follow-up: Q1 (n = 94), Q2 (n = 75), Q3 (n = 74), and Q4 (n = 52)
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P for non-linearity: 0.04
Serum 25(OH)D (nmol/L)
Fig. 2  Cross-sectional association between serum 25(OH)D and the 
number of depressive symptom score, adjusted for age, sex, BMI, 
education, smoking, physical activity, alcohol intake, season of blood 
sampling, centre, and self-reported diabetes
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A broader perspective
Several other observational studies also examined the 
association between 25(OH)D and depression in aged 
populations ≥60 years [9–15]. A study amongst 1282 
Dutch men and women aged 65–95 years from the Lon-
gitudinal Aging Study Amsterdam observed that persons 
in the highest 25(OH)D quartile had a lower probability 
of depression as measured with the Center for Epide-
miological Studies Depression Scale (CES-D) (β − 1.33 
P = 0.03) when compared to the lowest quartile [12]. The 
Os study, including 883 Chinese men ≥65 years, also 
Table 2  Associations between serum 25(OH)D at baseline with the number of depressive symptom score at baseline and after 2 years of vita-
min D supplementation with 15 µg/day, relative risks (95 % CI)
Model 1 is adjusted for age and sex
Model 2 is adjusted for age, sex, BMI, education, smoking, physical activity, alcohol intake, season of blood sampling, and centre
Model 3 is adjusted for age, sex, BMI, education, smoking, physical activity, alcohol intake, season of blood sampling, centre, and self-reported 
diabetes
a The associations at 2 years of follow-up were additionally adjusted for intervention group
Q1 Q2 Q3 Q4 P for trend
25(OH)D status (nmol/L) <36.7 36.7–53.3 53.4–71.7 >71.7
Baseline, n 704 714 709 712
Crude model (n = 2839) 1.0 0.69 (0.60–0.79)
P < 0.0001
0.69 (0.61–0.79)
P < 0.0001
0.68 (0.60–0.78)
P < 0.0001
P < 0.0001
Model 1 (n = 2839) 1.0 0.76 (0.66–0.87)
P < 0.0001
0.77 (0.67–0.88)
P = 0.0001
0.78 (0.68–0.90)
P = 0.0007
P < 0.0001
Model 2 (n = 2822) 1.0 0.78 (0.68–0.89)
P = 0.0003
0.79 (0.68–0.90)
P = 0.0007
0.82 (0.71–0.95)
P = 0.01
P < 0.0001
Model 3 (n = 2183) 1.0 0.71 (0.61–0.83)
P < 0.0001
0.73 (0.62–0.86)
P < 0.0001
0.83 (0.70–0.98)
P = 0.03
P = 0.0001
Follow-up, n 610 639 635 660
Crude model (n = 2544) 1.0 0.66 (0.58–0.76)
P < 0.0001
0.74 (0.64–0.85)
P < 0.0001
0.68 (0.59–0.78)
P < 0.0001
P < 0.0001
Model 1 (n = 2544) 1.0 0.72 (0.64–0.84)
P < 0.0001
0.82 (0.71–0.95)
P = 0.007
0.78 (0.67–0.90)
P = 0.0005
P < 0.0001
Model 2 (n = 2531)a 1.0 0.74 (0.64–0.84)
P < 0.0001
0.82 (0.70–0.95)
P = 0.007
0.79 (0.68–0.92)
P = 0.002
P < 0.0001
Model 3 (n = 1996)a 1.0 0.68 (0.59–0.79) 0.78 (0.66–0.93) 0.76 (0.64–0.90) P < 0.0001
Table 3  Associations between serum 25(OH)D and self-reported diabetes, PRs (95 % CI)
Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, BMI, education, smoking, physical activity, alcohol intake, season of blood 
sampling, and centre
25(OH)D status (nmol/L) n Q1 Q2 Q3 Q4 P for trend
4.1–36.7 36.7–53.4 53.4–71.7 71.7–193.6
Diabetes, n (cases) 569 (79) 560 (55) 543 (54) 536 (43)
Crude model 2208 1.0 0.71 (0.51–0.98) 0.72 (0.52–0.99) 0.58 (0.41–0.82) 0.003
Model 1 2208 1.0 0.68 (0.49–0.95) 0.69 (0.50–0.96) 0.56 (0.39–0.80) 0.002
Model 2 2191 1.0 0.80 (0.57–1.11) 0.81 (0.57–1.16) 0.77 (0.52–1.14) 0.20
Table 4  Associations of self-reported diabetes with the number 
of depressive symptom score at baseline, analysed with Poisson’s 
regression resulting in relative risks (95 % CI)
Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, 
BMI, education, smoking, physical activity, alcohol intake, season of 
blood sampling, and centre
Self-report diabetes
No (n = 2024) Yes (n = 231)
Crude model 1.0 1.22 (1.04–1.43)
Model 1 1.0 1.25 (1.07–1.46)
Model 2 1.0 1.17 (1.00–1.38)
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showed beneficial associations between 25(OH)D and 
depression, with an OR for depression of 0.46 (95 % CI 
0.22–0.98, P for trend = 0.004) in the highest quartile 
after adjustment for age, BMI, education, physical activ-
ity, number of activities of daily living, diet quality index, 
smoking, alcohol consumption, season, number of chronic 
diseases, cognitive performance, and serum (ln)PTH 
concentration [11]. Another large study that observed a 
beneficial association between 25(OH)D and depression 
was the Health Survey for England, which used data of 
2070 men and women ≥65 years [15]. To the best of our 
knowledge, none of the aforementioned studies accounted 
for gene profiles. We did, but we did not observe any 
association between vitamin D-related genetic make-up 
and the score of depressive symptoms, or interactions 
between 25(OH)D concentrations and vitamin D-related 
make-up. Kuningas and colleagues also explored associa-
tions between several VDR polymorphisms and observed 
an association between ApaI and depressive symptoms in 
563 Dutch Caucasian older adults [26]. However, as we 
did not observe any association between the vitamin D 
genes, we do consider the possibility that it is not a higher 
25(OH)D concentration that is responsible for a lower 
score of depressive symptoms, but that the observed asso-
ciation is explained by reverse causation or another factor 
that we could not control for in our analyses. Randomized 
controlled trials (RCTs) can provide more conclusive 
evidence on the direction of the association. However, to 
date, RCTs results are inconclusive. It has been argued 
that biological flaws may be the reason for the indecisive 
evidence, since several studies did not measure 25(OH)D 
concentrations, included participants with high 25(OH)D 
concentrations or used a relatively low dose of vitamin D 
[27].
Underlying mechanisms
A low vitamin D concentration may predispose to depres-
sion through several biological mechanisms. Vitamin D has 
amongst others been linked to an increase in serotonin pro-
duction [28] and a decrease in glucocorticoid-induced hip-
pocampal cell death [29]. Vitamin D has furthermore been 
hypothesized to play a role in synthesis of neurotrophins, 
production of acetylcholine and glutathione, and down-reg-
ulation of L-type voltage-sensitive calcium channel expres-
sion (reviewed in [5]). Vitamin D may also indirectly fight 
depressive symptoms via its proposed anti-inflammatory 
effect [30]. To further explore the underlying mechanisms, 
we investigated the possible role of diabetes. Due to a vari-
ety of disease-related stress factors, diabetics are consid-
ered to be at increased risk of developing depression [8]. 
With that, low serum 25(OH)D concentrations may also 
predispose to glucose intolerance [7]. Thus, mediation as 
well as modification effects could be expected to be pre-
sent. Nevertheless, fully adjusted models did not support 
an association between 25(OH)D and self-reported diabe-
tes. In addition, adding self-reported diabetes to the model 
on 25(OH)D and depression did not attenuate the observed 
association. Interaction analyses furthermore indicated that 
there was no difference in the score of depressive symp-
toms when having diabetes or not. All in all, we there-
fore conclude that our data do not support a mediation or 
modification effect of diabetes in the vitamin D–depression 
pathway.
Methodological considerations
A well-known limitation of observational studies is that it 
is not possible to say something about causality, specifi-
cally is the so-called exposure an actual risk factor or is 
it merely a consequence of the disease? Fortunately, we 
had the possibility to further explore this association in a 
longitudinal fashion, showing that 2 years of vitamin D 
supplementation with 15 µg per day did not change the 
association as observed at baseline. Interpreting these 
findings, however, is quite challenging, first of all because 
25(OH)D concentrations were not measured after 2 years 
of follow-up. It may be suggested that vitamin D supple-
mentation did not beneficially affect the score of depres-
sive symptoms and that the association is explained 
by an unknown other factor that is strongly correlated 
with 25(OH)D status. On the other hand, it may also be 
that participants in the lowest quartile did reach higher 
25(OH)D concentrations, but that these concentrations 
were still not high enough to decrease their probability of 
having a higher score of depressive symptoms relative to 
the other groups. Secondly, during 2 years of follow-up, 
participants may also have used vitamin D supplements 
on own initiative or medications that affect vitamin D 
metabolism, which may have affected the results. Another 
limitation of this study is that data were obtained from 
the B-PROOF study, an intervention trial examining the 
impact of vitamin B12 and folic acid on a variety of out-
comes, which may have interfered with our longitudinal 
analyses. Adjusting the associations for treatment group, 
however, did not substantially alter the associations. 
This study is also limited by the fact diabetes diagnosis 
is based on self-report. Strengths of this study were the 
large study population, possibility to study associations 
after 2 years of vitamin D supplementation, opportunity 
to adjust for important confounders, as well as the pos-
sibility to investigate the role of diabetes and of vitamin 
D-related genes that have been linked to vitamin D syn-
thesis, metabolism, and vitamin D receptor action.
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Conclusion
Our data support previously reported cross-sectional asso-
ciations between higher 25(OH)D concentrations and 
a decreased risk of depression. Our subsequent finding 
that 2 years of vitamin D supplementation did not trans-
late into a shift towards less depressive symptoms, how-
ever, raises concern about the temporality and causality 
of the association. No mediation or modification effect 
by diabetes was observed. To define the direction of the 
link between serum 25(OH)D and depression, there is a 
continuous need for prospective studies as well as well-
designed RCTs.
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